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Central picture legend: Real time CT 3D simulation fluoroscopic fusion 26 
 27 
Central message: Computer simulation can facilitate better patient selection for complex mitral 28 
structural interventions. Real-time fusion with fluoroscopy may optimize device deployment to 29 















Mitral valve annular calcification (MAC) may involve the mitral valve architecture and result in 32 
leaflet restriction. Although in such instances conventional mitral valve replacement (MVR) 33 
surgery remains the first line treatment for stenosis and regurgitation, the presence of MAC may 34 
require surgical debridement and result in ventricular or atrioventricular groove rupture and 35 
damage to the adjacent coronary arteries. With surgical morbidity and mortality remaining high1, 36 
there has been interest in less invasive transcatheter therapies using balloon inflatable 37 
transcatheter aortic valves. Although these have shown some early promise with reported 38 
technical success rates at specialist centers of up to 77%, periprocedural complications remain 39 
high. Immediate left ventricular outflow tract obstruction (LVOTO) occurs in up to 11.2%, a 40 
second valve is required in 14.7%, and valve embolization occurs in 4.3% of cases. Similarly, 1-41 
year cardiovascular and all-cause mortality remain high at 23.5% and 53.7%, respectively2,3. 42 
These observations suggest that there may be scope to refine patient selection and better guide 43 
procedural deployment of these valves in the MAC position. 44 
 45 
Case report 46 
An 83-year-old man with coronary artery disease, severe mixed mitral and aortic valve disease 47 
was referred for double valve surgery and coronary artery bypass grafting. At surgery, the patient 48 
underwent aortic valve replacement with a 23 mm Trifecta™ bioprosthesis (St. Jude Medical 49 
Inc.; St. Paul, MN) and single vessel grafting to the distal right coronary artery. Owing to the 50 
degree of MAC, surgical MVR was deferred in preference for an open valvotomy. At 12 months, 51 
the patient experienced a progression of symptoms and presented to our institute for 52 
consideration of transcatheter mitral valve replacement (TMVR) with an aortic bioprosthesis 53 














transthoracic echocardiography to evaluate the mitral stenosis and left ventricular function, 55 
multiphase cardiac CT to characterize the MAC and its geometry (Figure 1A, B). From the CT 56 
scans, additional three-dimensional computer models of the left heart were created using image 57 
dedicated segmentation techniques (Mimics software v18.0, Materialise, Leuven, Belgium) by 58 
FEops (Ghent, Belgium). The output of this segmentation process was subsequently used to 59 
generate a finite element mesh of the complete mitral valve apparatus, including the calcified 60 
mitral valve annulus, the mitral valve leaflets and chordae tendinae. Varying mechanical 61 
properties were automatically assigned to different tissue regions. Following this, detailed 62 
computer models of the valve that accurately represented mechanical device behavior (e.g. 63 
braided wires and locking mechanism) were virtually implanted in the patient-specific left heart 64 
models using finite element simulations. All steps of the clinical implantation were respected. 65 
This included valve size selection, implantation position and computer simulation based on finite 66 
element analysis to predict calcium deformation, implantation height and LVOTO following 67 
virtual device deployment (Figure 1C)4. Data analysis predicted an optimal outcome for TMVR 68 
in MAC with no risk of LVOTO or paravalvular regurgitation provided that the valve was 69 
deployed at an intermediate height between the left atrium and left ventricle (Video 1). 70 
 71 
Subsequent valve implantation was performed using a transvenous, transseptal approach under 72 
general anesthesia with real time 3D computer simulation fluoroscopic image fusion (GE Valve 73 
Assist 2, GE Healthcare, Buc, France) and transesophageal echocardiography guidance 74 
(Supplementary Material). Anatomical landmark fusion enabled optimal transseptal crossing, 75 
balloon dilatation of the interatrial septum and crossing of the mitral valve with a Safari2™ 76 














the 29 mm Edwards SAPIEN 3 valve to the optimal intermediate deployment zone, following 78 
which the valve was deployed using the nominal volume (-2 mL), under rapid ventricular pacing 79 
(Figure 1D). Peri-procedural transesophageal echocardiography confirmed optimal position of 80 
the valve with no LVOTO (LVOT gradient pre-procedure 3.7 mmHg vs. 11.5 mmHg post-81 
procedure), or paravalvular regurgitation. At 6 weeks, the patient’s symptoms had improved to 82 
NYHA Class II with transthoracic echocardiography and cardiac CT showing an excellent result, 83 
consistent with the expected outcome from pre-procedural planning (Figure 1E, F). 84 
 85 
Limitations 86 
Currently, the application of computer simulation to patients with MAC is of investigational use 87 
only. The practicality and commercial cost of this technique cannot be answered at this stage. 88 
 89 
Conclusions 90 
This case demonstrates the potential of bioengineering and computer simulation to facilitate 91 
better patient selection for complex mitral structural interventions. Incorporation of this 92 
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Figure legend 112 
Figure 1A: Cardiac CT scan 3-chamber view showing the bioprosthetic aortic valve in situ and 113 
the mitral valve annular calcification (*). Figure 1B: Cardiac CT scan short axis view at the 114 
level of the mitral valve annulus showing the heavy annular calcification, its elliptical geometry 115 
and non-circumferential distribution. The length of the anterior leaflet of the mitral valve was 22 116 
mm. There was mild thickening at the basal septum of 14 mm but the remainder of the 117 
myocardium had normal wall thickness at 10 mm. Figure 1C: Computer simulated image using 118 
cardiac CT segmentation and the application of finite element analysis. The model accounts for 119 
the mitral valve annulus calcification, the mitral valve leaflets and the basal, strut and mitral 120 
valve leaflet chordae tendinae. From the model, various sizes of transcatheter valves can be 121 
virtually deployed into the mitral valve annulus at various heights, enabling prediction of 122 
calcium deformation, paravalvular regurgitation and left ventricular outflow tract obstruction. 123 
The image shows the virtual deployment of an Edwards Sapien 3 valve in the mitral valve 124 
annulus. Figure 1D: Real time CT 3D simulation fluoroscopic fusion showing the guidewire 125 
crossing the mitral valve. The optimal implant zone is marked by the orange and green lines 126 
(indicating the superior and inferior boundaries of the intended valve position, respectively). The 127 
undeployed Sapien 3 valve is seen being positioned between these points over the guidewire. 128 
Figure 1E: Post-procedural cardiac CT 3-chamber view at three months showing the deployed 129 
Sapien 3 valve in close apposition with the annulus. and there was no left ventricular outflow 130 
obstruction. Figure 1F: Post-procedural cardiac CT – short axis view showing the deployment of 131 















Ao – aorta, LA – left atrium, LV – left ventricle, MV – mitral valve, TMVR – transcatheter 134 















Video legend 137 
Video 1 138 
Computer simulation demonstrating the deployment of an Edwards Sapien 3 valve within the 139 
mitral annular calcification at an intermediate deployment zone. The video demonstrates the 140 















Supplemental Material 143 
 144 
Video 2 145 
Periprocedural transesophageal echocardiogram – 143o view demonstrating the presence of 146 
mitral annular calcification, severe leaflet restriction and mitral stenosis. 147 
 148 
Video 3 149 
Periprocedural transesophageal echocardiogram 3D volume rendered surgical view of the mitral 150 
valve showing severe mitral annular calcification and mitral valve leaflet restriction. 151 
 152 
Video 4 153 
Cardiac CT fluroscopic landmark fusion showing the key anatomical landmarks from the CT 154 
scan overlaid onto the fluroscopic images. The yellow circle represents the superior vena cava 155 
boundary, the inferior green circle the inferior vena cava boundary, the light blue the mitral 156 
annular calcification, the orange central circle the fossa ovalis, the orange superior circle the 157 
aortic valve and the yellow and green vertical rings the superior and inferior boundaries of the 158 
ideal implantation zone for the Sapien 3 valve. 159 
 160 
Video 5 161 
Cardiac CT fluroscopic landmark fusion with the same landmark coding as Video 4. The video 162 
shows the positioning of the Sapien 3 valve at the simulated optimal position and the 163 
superimposition of the 3D volume rendered left atrium onto the fluoroscopy along with the 164 














Video 6 166 
Periprocedural transesophageal echocardiogram – 125o view with color Doppler showing no 167 
paravalvular regurgitation across the implanted Sapien 3 valve and no left ventricular outflow 168 
tract obstruction. 169 
 170 
Video 7 171 
Periprocedural transesophageal echocardiogram – 3D volume rendered surgical view of the 172 
implanted Sapien 3 valve showing normal leaflet motion and good device stability. 173 
 174 
Video 8 175 
Post procedural transthoracic echocardiogram at 6 weeks – apical 4 chamber view with color 176 
Doppler showing no paravalvular regurgitation and no LVOTO. 177 
 178 
Video 9 179 
Post procedural ECG gated multiphase CT at 6 weeks showing positioning of the Sapien 3 valve 180 
at an intermediate implantation height with no significant left ventricular outflow tract 181 
obstruction in the 3-chamber view. 182 
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